Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 comparator-controlled trial of LY3209590 versus insulin degludec in insulin-naïve type 2 diabetes mellitus
2019-003339-53Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in hemoglobin A1c (HbA1c). Started Mar 2020; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-003339-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003339-53.